低甲基化药物治疗慢性粒单核细胞白血病的自然史
本文回顾性分析了151例接受低甲基化药物(HMA)治疗的慢性粒单核细胞白血病(CMML)患者,中位随访17个月,总缓解率75%,完全缓解率41%,中位总生存24个月。地西他滨组的完全缓解率(58.3%)显著高于阿扎胞苷组(20.6%)(P < .001)。HMA治疗失败后预后差,中位总生存仅7个月。
要点
- HMA治疗CMML的完全缓解率地西他滨组58.3% vs 阿扎胞苷组20.6%(P < .001)。
- 中位总生存24个月(95%CI:20-28),中位无事件生存14个月(95%CI:11-17)。
- HMA治疗失败后中位总生存7个月(95%CI:3-12),部分患者转化为急性髓系白血病。
核心结论
- HMA对CMML有效,但需要新的药物和联合方案;该数据可作为CMML进一步药物开发的基准。
研究设计与样本
- 回顾性系列研究,纳入151例接受HMA治疗的CMML患者,诊断时平均年龄69岁(范围50-88)。
主要发现
- 根据CMML特异性预后评分系统(CPSS):低危17例(15%),中危-1 45例(39%),中危-2 42例(36%),高危12例(10%)。
- 35例(23%)接受阿扎胞苷单药,73例(48%)接受地西他滨单药,43例(29%)接受联合治疗。
- 中位随访17个月,总缓解率75%,完全缓解率41%;中位总生存24个月(95%CI:20-28),中位无事件生存14个月(95%CI:11-17)。
- 多因素分析显示,年龄<70岁、较高血红蛋白水平、外周血无原始细胞及较低CPSS细胞遗传学风险预示更好的总生存。
- 66例(50%)出现HMA治疗失败:原发性26例(34%),继发性50例(66%),其中35例(46%)转化为急性髓系白血病;HMA失败后中位总生存7个月(95%CI:3-12)。
关键数值与推荐
- 完全缓解率在地西他滨组为58.3%,在阿扎胞苷组为20.6%(P < .001)。
- 13例(9%)在中位4个周期HMA治疗后接受异基因造血干细胞移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n = 151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15%) were low-risk, 45 (39%) intermediate-1 risk, 42 (36%) intermediate-2, and 12 (10%) high-risk. 35 (23%) patients received single agent azacitidine, 73 (48%) single agent decitabine, and 43 (29%) combinations. With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR). Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17). By multivariate analysis, age < 70 years, higher levels of hemoglobin, absence of blast in peripheral blood and lower CPSS cytogenetic risk predicted for better OS. CR was significantly higher in those patients treated with decitabine (58.3%) when compared with azacitidine (20.6%) (P < .001). 13 patients (9%) received allo-SCT after a median of 4 cycles of HMA. 66 patients (50%) had HMA failure: 26 primary (34%) and 50 secondary (66%), including 35 (46%) that transformed to AML. Outcomes after HMA failure were poor with OS of 7 months (95%CI: 3-12). In conclusion, HMA are effective in CMML but new agents and combinations are needed. This data could be a benchmark for further drug development in CMML.
引用
- Alfonso A, Montalban-Bravo G, Takahashi K, et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017. PMID: 28370097. doi:10.1002/ajh.24735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。